IceCure Medical (NASDAQ:ICCM) Stock Rating Upgraded by Wall Street Zen

IceCure Medical (NASDAQ:ICCM) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IceCure Medical in a report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $2.64.

IceCure Medical Stock Performance

Shares of ICCM stock opened at $0.59 on Friday. The stock has a market cap of $40.53 million, a price-to-earnings ratio of -2.27 and a beta of 0.29. IceCure Medical has a 52-week low of $0.54 and a 52-week high of $1.66. The firm has a fifty day moving average of $0.66 and a 200-day moving average of $0.81.

IceCure Medical (NASDAQ:ICCM) last issued its earnings results on Wednesday, November 19th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The firm had revenue of $0.85 million during the quarter, compared to analyst estimates of $0.63 million. IceCure Medical had a negative net margin of 513.95% and a negative return on equity of 243.68%. On average, sell-side analysts predict that IceCure Medical will post -0.28 earnings per share for the current year.

Institutional Trading of IceCure Medical

An institutional investor recently bought a new position in IceCure Medical stock. Concurrent Investment Advisors LLC acquired a new position in shares of IceCure Medical Ltd. (NASDAQ:ICCM) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 78,285 shares of the company’s stock, valued at approximately $48,000. Concurrent Investment Advisors LLC owned about 0.11% of IceCure Medical at the end of the most recent quarter. 0.62% of the stock is owned by hedge funds and other institutional investors.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.